v3.26.1
Contingent Consideration - Schedule of Reconciliation of the Beginning and Ending Balances Related to the Contingent Consideration (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at beginning of period $ 31,258 $ 47,340
Change in fair value recognized in earnings $ 2,391 $ 7,660
Change in fair value recognized in earnings, location Contingent consideration loss Contingent consideration loss
Milestone payments $ 0 $ (25,000)
Reclassification to Other current liabilities (33,443)  
Balance at end of period 206 30,000
USWM Acquisition    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at beginning of period 0 47,340
Change in fair value recognized in earnings 0 7,660
Milestone payments 0 (25,000)
Reclassification to Other current liabilities 0  
Balance at end of period 0 30,000
Sage Therapeutics, Inc.    
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]    
Balance at beginning of period 31,258 0
Change in fair value recognized in earnings 2,391 0
Milestone payments 0 0
Reclassification to Other current liabilities (33,443)  
Balance at end of period $ 206 $ 0